IFNB1 and myeloid sarcoma: That the increase of LAG3 levels by IFN-β may serve to attenuate cell activation in both B and T cells is in line with the modulatory role attributed to IFN-β in MS, the augmentation of autoimmunity by LAG3 deficiency [58], and the increased activation of B cells occurring in MS [59].